サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428439

体軸性脊椎関節炎（axSpA）の世界市場レポート 2024

Axial Spondyloarthritis (axSpA) Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
体軸性脊椎関節炎（axSpA）の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

体軸性脊椎関節炎（axSpA）の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.9%の年間複合成長率（CAGR）で81億8,000万米ドルに成長すると予想されます。予測期間で予想される成長は、体軸性脊椎関節炎（axSpA）のバイオマーカー特定の進歩、オーダーメイド治療の開発、デジタル医療ソリューションの統合、治療選択肢の拡大、支援的なヘルスケア政策など、さまざまな要因に起因すると考えられます。この期間中に予想される主な動向には、axSpAの早期介入戦略、患者中心のケアアプローチの採用、遠隔医療と遠隔診療の利用増加、疾患メカニズムに関する進行中の調査、axSpAの管理における共有意思決定の促進などが含まれます。

脊椎関節炎の有病率の上昇は、体軸性脊椎関節炎（axSpA）市場の成長の原動力となると予想されます。脊椎関節炎は、主に脊椎や仙腸関節などの軸骨格に影響を及ぼす慢性疾患で、高齢化と軽度の転倒や事故による脊椎損傷に関連する症例が増加しています。さまざまな治療法は、axSpAに苦しむ人の痛みを管理し、炎症を制御し、生活の質を改善することを目的としています。たとえば、関節炎患者を支援する英国の慈善団体、ヴァーサス・関節炎の筋骨格健康報告書2023年版によると、2022年には約6万人が軸性脊椎関節炎に罹患し、毎年約2,200人の成人がこの疾患と診断されています。したがって、軸性脊椎関節炎の有病率の上昇は、axSpa市場の成長を促進する重要な推進力です。

体軸性脊椎関節炎（axSpA）市場の予想される成長は、高齢者人口の増加によって牽引されると予想されます。「高齢化人口」という用語は、人口内の高齢者の割合の増加または割合の増加を特徴とする人口動態の変化を指します。高齢者におけるaxSpAの管理は、関節機能と可動性の強化、生活の質の向上、脊椎構造損傷の予防、ヘルスケア費の削減、障害予防、最適化された治療アプローチなど、いくつかの利点をもたらします。世界保健機関の2022年 10月のデータによると、2030年までに世界中で6人に1人が60歳以上となり、2050年までにこの年齢層は倍増して約21億人になると予測されています。英国では、英国議会下院図書館による2021年 6月の統計によると、2043年までに高齢者人口は英国総人口の約24%、約1,740万人を占めるようになることが示唆されています。したがって、高齢化人口の増加は、体軸性脊椎関節炎（axSpA）市場の拡大を促進する重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の体軸性脊椎関節炎（axSpA）市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 強直性脊椎炎（AS）
  • 非X線撮影による体軸性脊椎関節炎（nr-axSpA）
  • 世界の体軸性脊椎関節炎（axSpA）市場、商業治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗腫瘍壊死因子療法（TNF）
  • 抗インターロイキン療法（IL）
  • 抗ヤヌスキナーゼ療法（JAK）
  • 世界の体軸性脊椎関節炎（axSpA）市場、剤形別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 錠剤
  • 注射
  • 世界の体軸性脊椎関節炎（axSpA）市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腫瘍壊死因子（TNF）アルファ阻害剤
  • 非ステロイド性抗炎症薬（NSAID）
  • 従来の疾患修飾性抗リウマチ薬
  • 糖質コルチコイド
  • インターロイキン遮断薬
  • 世界の体軸性脊椎関節炎（axSpA）市場、最終用途用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局ストア

第7章 地域および国の分析

  • 世界の体軸性脊椎関節炎（axSpA）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の体軸性脊椎関節炎（axSpA）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 体軸性脊椎関節炎（axSpA）市場の競合情勢
  • 体軸性脊椎関節炎（axSpA）市場企業プロファイル
    • Johnson and Johnson Private Limited
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck and Co. Inc.
    • AbbVie Inc.

第31章 その他の大手および革新的な企業

  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AstraZeneca plc.
  • Abbott Laboratories
  • GSK plc.
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Biogen Inc.
  • Vertex Pharmaceuticals Incorporated
  • UCB SA
  • Boehringer Ingelheim International GmbH.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14284

Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition primarily affecting the axial skeleton, including the spine and sacroiliac joints, leading to persistent back pain and stiffness. The condition is characterized by inflammation in the sacroiliac joints.

The main types of axial spondyloarthritis (axSpA) include Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing Spondylitis (AS) is a specific form of arthritis that affects the ligaments and joints in the spine. Commonly used over-the-counter anti-inflammatory medications, such as naproxen and ibuprofen, are often employed to alleviate pain, inflammation, and muscle stiffness, with the goal of delaying complications and spinal deformities. Various commercialized therapies are available for the treatment of axial spondyloarthritis, including anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK). These therapies come in different dosage forms, such as tablets and injections, and are utilized for different types of treatments, including tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAID), conventional disease-modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These treatments are distributed through different channels, including hospital pharmacies, retail pharmacies, and online pharmacy stores.

The axial spondyloarthritis (axSpA) market research report is one of a series of new reports from The Business Research Company that provides axial spondyloarthritis (axSpA) market statistics, including axial spondyloarthritis (axSpA) industry global market size, regional shares, competitors with an axial spondyloarthritis (axSpA) market share, detailed axial spondyloarthritis (axSpA) market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axSpA) industry. This axial spondyloarthritis (axSpA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth observed in the historical period can be attributed to several factors, including improved diagnostic criteria for axial spondyloarthritis (axSpA), advancements in biological treatments, increased awareness of the disease, progress in genetic research related to axSpA, and advancements in clinical trials. These factors collectively contributed to the developments and progress in the understanding and management of axial spondyloarthritis during the specified historical timeframe.

The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period can be attributed to various factors, including advancements in biomarker identification for axial spondyloarthritis (axSpA), the development of tailored therapies, integration of digital health solutions, expansion of treatment options, and supportive healthcare policies. Key trends expected during this period encompass early intervention strategies for axSpA, the adoption of patient-centric care approaches, increased utilization of telemedicine and remote consultations, ongoing research on disease mechanisms, and the promotion of shared decision-making in the management of axSpA.

The rising prevalence of spondyloarthritis is expected to be a driving force behind the growth of the axial spondyloarthritis (axSpa) market. Spondyloarthritis, a chronic condition primarily affecting the axial skeleton, such as the spine and sacroiliac joints, has seen an increase in cases linked to the aging population and spinal injuries resulting from minor falls or accidents. Various treatments aim at managing pain, controlling inflammation, and improving the quality of life for individuals suffering from axSpA. For example, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity supporting people with arthritis, approximately 60,000 individuals were affected by axial spondyloarthritis in 2022, with around 2,200 adults diagnosed annually with this condition. Hence, the rising prevalence of axial spondyloarthritis is a significant driver fueling the growth of the axSpa market.

The anticipated growth of the axial spondyloarthritis (axSpA) market is expected to be driven by the increasing elderly population. The term 'aging population' denotes a demographic shift characterized by a growing proportion or higher percentage of older individuals within a populace. Managing axSpA among the elderly yields several benefits, including enhanced joint function and mobility, improved quality of life, prevention of spinal structural damage, reduced healthcare expenses, disability prevention, and optimized treatment approaches. As per the World Health Organization's data from October 2022, it's projected that by 2030, globally, 1 in 6 individuals will be aged 60 or above, while by 2050, this age group will double to approximately 2.1 billion people. In the UK, statistics from June 2021 by the UK Parliament's House of Commons Library suggest that by 2043, the senior population will constitute around 24% of the total UK population, comprising about 17.4 million individuals. Therefore, the growing aging population is a significant driver fostering the expansion of the axial spondyloarthritis (axSpA) market.

Product innovation stands out as a leading trend gaining traction in the axial spondyloarthritis (axSpA) market. Key companies in this field are actively developing novel drugs to maintain their market standing. For instance, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is designed for treating active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adults exhibiting objective signs of inflammation indicated by elevated C-reactive protein. These approvals within the European Union represent the first global marketing authorizations for the treatment of axial spondyloarthritis using this drug.

Significant investments are a focal point for major companies operating in the axial spondyloarthritis (axSpA) market to gain a competitive advantage. Notably, the investment revolves around the development of Izokibep, a unique IL-17A inhibitor intended for managing inflammatory diseases such as psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). For example, in September 2022, Acelyrin Inc., a biopharmaceutical company based in the US, announced a $300 million investment. Izokibep, a mimetic antibody simulating interleukin-17A (IL-17A), aims to overcome the limitations of monoclonal antibodies and has shown promising tolerability in clinical trials. This substantial investment is directed towards securing potential approvals for Izokibep as a treatment for various inflammatory conditions and advancing its clinical development. The company's commitment to pioneering immunology therapies and addressing unmet medical needs in treating inflammatory disorders is evident through its emphasis on securing significant funding and advancing the development of Izokibep.

In April 2022, Ampersand Health, a UK-based research company, entered into a partnership with UCB SA for an undisclosed amount. This collaboration is intended to benefit patients dealing with axial spondyloarthritis (axSpA) by leveraging the innovative digital solutions from Ampersand Health and the clinical expertise of UCB SA. The aim of the partnership is to enhance the management of symptoms for individuals with axial spondyloarthritis and improve their overall quality of life. UCB SA, the Belgium-based biopharmaceutical company involved in neurology and immunology therapies, is known for providing solutions in the field of axial spondyloarthritis.

Major companies operating in the axial spondyloarthritis (axspa) market report are Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC, Celgene Corporation, Pozen Inc.

North America was the largest region in the axial spondyloarthritis (axSpA) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the axial spondyloarthritis (axspa) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Axial Spondyloarthritis (axSpA) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on axial spondyloarthritis (axspa) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for axial spondyloarthritis (axspa) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The axial spondyloarthritis (axspa) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Types: Ankylosing spondylitis (AS); Non-radiographic axial spondyloarthritis (nr-axSpA)
  • 2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF); Anti-Interleukin Therapy (IL); Anti-Janus Kinase Therapy (JAK)
  • 3) By Dosage Form: Tablets; Injections
  • 4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors; Non-steroidal anti-inflammatory drugs (NSAID); Conventional Disease Modifying Anti-Rheumatic Drugs; Glucocorticoids; Interleukin Blockers
  • 5) By End-Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores
  • Companies Mentioned: Johnson and Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Axial Spondyloarthritis (axSpA) Market Characteristics

3. Axial Spondyloarthritis (axSpA) Market Trends And Strategies

4. Axial Spondyloarthritis (axSpA) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Axial Spondyloarthritis (axSpA) Market Size and Growth

  • 5.1. Global Axial Spondyloarthritis (axSpA) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Axial Spondyloarthritis (axSpA) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Axial Spondyloarthritis (axSpA) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Axial Spondyloarthritis (axSpA) Market Segmentation

  • 6.1. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ankylosing spondylitis (AS)
  • Non-radiographic axial spondyloarthritis (nr-axSpA)
  • 6.2. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-tumor Necrosis Factor Therapy (TNF)
  • Anti-Interleukin Therapy (IL)
  • Anti-Janus Kinase Therapy (JAK)
  • 6.3. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tablets
  • Injections
  • 6.4. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tumor necrosis factor (TNF) Alpha Inhibitors
  • Non-steroidal anti-inflammatory drugs (NSAID)
  • Conventional Disease Modifying Anti-Rheumatic Drugs
  • Glucocorticoids
  • Interleukin Blockers
  • 6.5. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacy Stores

7. Axial Spondyloarthritis (axSpA) Market Regional And Country Analysis

  • 7.1. Global Axial Spondyloarthritis (axSpA) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Axial Spondyloarthritis (axSpA) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Axial Spondyloarthritis (axSpA) Market

  • 8.1. Asia-Pacific Axial Spondyloarthritis (axSpA) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Axial Spondyloarthritis (axSpA) Market

  • 9.1. China Axial Spondyloarthritis (axSpA) Market Overview
  • 9.2. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Axial Spondyloarthritis (axSpA) Market

  • 10.1. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Axial Spondyloarthritis (axSpA) Market

  • 11.1. Japan Axial Spondyloarthritis (axSpA) Market Overview
  • 11.2. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Axial Spondyloarthritis (axSpA) Market

  • 12.1. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Axial Spondyloarthritis (axSpA) Market

  • 13.1. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Axial Spondyloarthritis (axSpA) Market

  • 14.1. South Korea Axial Spondyloarthritis (axSpA) Market Overview
  • 14.2. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Axial Spondyloarthritis (axSpA) Market

  • 15.1. Western Europe Axial Spondyloarthritis (axSpA) Market Overview
  • 15.2. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Axial Spondyloarthritis (axSpA) Market

  • 16.1. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Axial Spondyloarthritis (axSpA) Market

  • 17.1. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Axial Spondyloarthritis (axSpA) Market

  • 18.1. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Axial Spondyloarthritis (axSpA) Market

  • 19.1. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Axial Spondyloarthritis (axSpA) Market

  • 20.1. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Axial Spondyloarthritis (axSpA) Market

  • 21.1. Eastern Europe Axial Spondyloarthritis (axSpA) Market Overview
  • 21.2. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Axial Spondyloarthritis (axSpA) Market

  • 22.1. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Axial Spondyloarthritis (axSpA) Market

  • 23.1. North America Axial Spondyloarthritis (axSpA) Market Overview
  • 23.2. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Axial Spondyloarthritis (axSpA) Market

  • 24.1. USA Axial Spondyloarthritis (axSpA) Market Overview
  • 24.2. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Axial Spondyloarthritis (axSpA) Market

  • 25.1. Canada Axial Spondyloarthritis (axSpA) Market Overview
  • 25.2. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Axial Spondyloarthritis (axSpA) Market

  • 26.1. South America Axial Spondyloarthritis (axSpA) Market Overview
  • 26.2. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Axial Spondyloarthritis (axSpA) Market

  • 27.1. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Axial Spondyloarthritis (axSpA) Market

  • 28.1. Middle East Axial Spondyloarthritis (axSpA) Market Overview
  • 28.2. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Axial Spondyloarthritis (axSpA) Market

  • 29.1. Africa Axial Spondyloarthritis (axSpA) Market Overview
  • 29.2. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Axial Spondyloarthritis (axSpA) Market Competitive Landscape And Company Profiles

  • 30.1. Axial Spondyloarthritis (axSpA) Market Competitive Landscape
  • 30.2. Axial Spondyloarthritis (axSpA) Market Company Profiles
    • 30.2.1. Johnson and Johnson Private Limited
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck and Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Axial Spondyloarthritis (axSpA) Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. AstraZeneca plc.
  • 31.5. Abbott Laboratories
  • 31.6. GSK plc.
  • 31.7. Eli Lilly and Company
  • 31.8. Takeda Pharmaceutical Company Limited
  • 31.9. Gilead Sciences Inc.
  • 31.10. Teva Pharmaceutical Industries Ltd.
  • 31.11. Regeneron Pharmaceuticals Inc.
  • 31.12. Biogen Inc.
  • 31.13. Vertex Pharmaceuticals Incorporated
  • 31.14. UCB S.A.
  • 31.15. Boehringer Ingelheim International GmbH.

32. Global Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking

33. Global Axial Spondyloarthritis (axSpA) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market

35. Axial Spondyloarthritis (axSpA) Market Future Outlook and Potential Analysis

  • 35.1 Axial Spondyloarthritis (axSpA) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Axial Spondyloarthritis (axSpA) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Axial Spondyloarthritis (axSpA) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer